Skip to main content
Premium Trial:

Request an Annual Quote

Opko Health Licenses Protein Vaccine Technology for Viral Infections

Premium

Opko Health announced this week that it has obtained the exclusive worldwide rights from Taiwan's Academia Sinica to a novel technology to develop protein vaccines against influenza and other viral infections.

Terms of the licensing deal were not disclosed.

Opko said that it is forming a Taiwanese subsidiary to collaborate with Academia Sinica in developing the first product from the technology platform, a universal flu vaccine.

The arrangement marks the latest step away from the RNAi field for Opko, which bills itself primarily as an ophthalmics firm. As reported by RNAi News last month, the company has conducted a number of business transactions over 2009, including investments in antibody and small-molecule drug developers, raising questions about its commitment to the gene-silencing technology (see RNAi News, 6/25/2009).

The Scan

Plan Rebuffed

The Associated Press reports China has rejected the World Health Organization's proposal to include the lab-leak theory in the next phase of its investigation into the origins of SARS-CoV-2.

Opossum Change

Researchers from Riken have used CRISPR to edit marsupial genomes, as Technology Review reports.

In the Ice

Cosmos magazine reports that researchers have uncovered more than two dozen ancient viruses in a Tibetan glacier.

Nature Papers Present Method to Uncover Differential RNA Modifications, Neutrophils in Innate Immune Response

In Nature this week: computational approach to identifying differential RNA modifications, and more.